Suppr超能文献

纳多洛尔或纳多洛尔联合5-单硝酸异山梨酯对肝硬化患者肾功能及腹水形成的长期影响。GTIP 威尼托门静脉高压研究组

Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale.

作者信息

Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, Angeli P, Cavallarin G, Sebastianelli G

机构信息

Department of Clinical Medicine, University of Padua, Italy.

出版信息

Hepatology. 1995 Sep;22(3):808-13. doi: 10.1002/hep.1840220318.

Abstract

The association beta-blockers plus nitrates has been reported to impair renal function and renal sodium handling, leading to increased risk of development of ascites, or worsening of a preexisting ascites, or increase in the requirements of diuretic agents. In 81 patients with cirrhosis and esophageal varices, participating in a multicenter controlled clinical trial of prophylaxis of variceal bleeding comparing nadolol (NAD) plus isosorbide-5-mononitrate (I5M) with NAD alone, renal function, presence of ascites, and diuretic requirements were assessed at inclusion and after 6 months of follow-up. No significant variation in s-urea or s-creatinine was observed in either group, Three patients in the nadolol group and two in the NAD plus I5M developed ascites at 6 months (P = .70), and a need to increase diuretic regimen was observed in four and three patients, respectively (P = .76). Decrease in heart rate and in mean arterial pressure was similar in the two groups. There was a significant correlation between increases in s-creatinine and decrease in mean arterial pressure in the whole series (P = .015). Only in patients treated with the association was there a significant larger proportion of patients ascitic who became anascitic, than of patients anascitic who became ascitic (P = .03). In patients treated with the association, there was a significantly larger decrease in hepatic venous pressure gradient (P = .05). It is concluded that patients treated with the association NAD plus I5M are not at increased risk of developing renal dysfunction or worsening of ascites compared with patients treated with NAD alone.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

据报道,β受体阻滞剂与硝酸盐联用会损害肾功能和肾脏对钠的处理,导致腹水形成风险增加、原有腹水恶化或利尿剂需求增加。在一项多中心对照临床试验中,81例肝硬化和食管静脉曲张患者参与了比较纳多洛尔(NAD)加5-单硝酸异山梨酯(I5M)与单用NAD预防静脉曲张出血的研究,在入组时和随访6个月后评估了肾功能、腹水情况及利尿剂需求。两组患者的血清尿素或血清肌酐均无显著变化。纳多洛尔组有3例患者、NAD加I5M组有2例患者在6个月时出现腹水(P = 0.70),分别有4例和3例患者需要增加利尿剂治疗方案(P = 0.76)。两组心率和平均动脉压的下降相似。在整个研究系列中,血清肌酐升高与平均动脉压下降之间存在显著相关性(P = 0.015)。仅在联合用药治疗的患者中,腹水消退的患者比例显著高于腹水出现的患者比例(P = 0.03)。在联合用药治疗的患者中,肝静脉压力梯度显著下降(P = 0.05)。得出的结论是,与单用NAD治疗的患者相比,接受NAD加I5M联合治疗的患者发生肾功能障碍或腹水恶化的风险并未增加。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验